CAMERA Newsletters

Health Canada has approved Leqembi (lecanemab), the first Alzheimer’s treatment in Canada aimed at the disease’s biology for people with early symptoms—we outline access and safety considerations. We also explain how loneliness raises dementia risk and ways to stay connected, recap our team’s week at AAIC in Toronto, celebrate Dr. Jenny Rabin’s promotion to Associate Professor, and share progress toward our 300-participant goal.

In this issue, we explore how sleep impacts brain health and dementia risk, share updates on new Alzheimer’s medications under review in Canada, and highlight CAMERA findings showing the need for more inclusive dementia screening tools. We also celebrate Madeline Wood Alexander’s Research Excellence Award and invite you to AAIC For All, a free community event in Toronto this July. With your support, we continue advancing equity in brain health research.

In this issue, we explore conditions that can mimic dementia but are treatable, such as depression, sleep apnea, and vitamin deficiencies. We celebrate Dr. Rabin’s Early Career Award and share highlights from our team’s community outreach at the Seniors Active Living Fair. Our research was also featured in The New York Times and on a BBC podcast, advancing knowledge on women’s brain health and menopause. We continue working toward our recruitment goal of 300 participants.